Categories Health Care, IPO
Everything you need to know about OS Therapies’ upcoming IPO
The company has applied to list its shares for trading on NYSE American under the symbol OSTX
There has been a strong uptick in IPO activity this year compared to 2023 when the market witnessed a slowdown. In the first half, the number of IPOs grew in double digits, led by the technology and biotech sectors. Recently, OS Therapies Incorporated, a clinical-stage biopharmaceutical company focused on the development of treatments for Osteosarcoma, filed papers with the Securities and Exchange Commission to go public.
The Offering
The company plans to offer around 2.0 million shares of its common stock in the initial public offering, at an estimated price of $4.0 per share. It has applied to list the shares for trading on the NYSE American under the symbol OSTX. Brookline Capital Markets, a division of Arcadia Securities, is the underwriter for the offering. The underwriters have been granted the option to purchase up to 300,000 additional shares, exercisable for 45 days.
The company is looking to raise around $6.74 million, or $7.84 million if the underwriters exercise in full their option to purchase additional shares, from the offering. Around $4.2 million of the proceeds will be used for advancing the clinical development of OST-HER2, the lead core product candidate for Osteosarcoma. The company intends to use about $1.2 million to advance the development of its ovarian cancer drug OST-tADC.
The remainder of the net proceeds will be used for the discovery and development of new product candidates and working capital and other general corporate purposes. As of now, the company doesn’t have plans to pay cash dividends to stockholders, rather it will retain all available funds and any future earnings to fund the growth and development of its business.
Financials
OS Therapies was founded in April 2018 by Paul Romness, who has served as the president and chief executive officer since then. For the three months ended March 2024, the company reported a net loss applicable to shareholders of $1.49 million or $0.25 per share, compared to a loss of $1.88 million or $0.35 per share in the corresponding period last year. Research and development expenses were $0.36 million during the three months, lower than the $0.75 million reported in the year-ago quarter.
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
IPO Alert: OneStream prepares to go public. Here’s what you need to know
After a slow start to the year, the IPO market gathered momentum in the first half as aspirants flocked to stock exchanges, led by the technology and healthcare sectors. A
Earnings Preview: Will Citigroup’s (C) turnaround efforts be reflected in Q2 report?
For Citigroup Inc. (NYSE: C), 2023 was an important year when it initiated a major organizational restructuring to become a streamlined and more efficient business. In the new phase of
A look at Electronic Arts’ (EA) expectations for the near term
Shares of Electronic Arts (NASDAQ: EA) stayed red on Friday. The stock has gained 6% over the past three months. The company saw its revenues decline during the fourth quarter
